Headlines about Conatus Pharmaceuticals (NASDAQ:CNAT) have been trending positive recently, AlphaOne Sentiment reports. The research firm, a subsidiary of Accern, rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a news impact score of 0.34 on AlphaOne’s scale. AlphaOne also assigned news articles about the biotechnology company an impact score of 33 out of 100, meaning that recent news coverage is unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have impacted AlphaOne’s rankings:
- Conatus Announces Completion of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (finance.yahoo.com)
- Revisiting Conatus Pharmaceuticals Due To Recent Pipeline Expansion Talks (seekingalpha.com)
- DURECT Corporation’s (DRRX) registers a price change of 10.00% while Conatus Pharmaceuticals Inc.’s (CNAT … – Stocks Gallery (stocksgallery.com)
- SunTrust Banks Research Analysts Lower Earnings Estimates for Conatus Pharmaceuticals Inc (CNAT) (americanbankingnews.com)
- Analysts Recommendations Conatus Pharmaceuticals Inc. (CNAT) (nyhetsbanken.info)
Several equities research analysts have weighed in on the company. Aegis reaffirmed a “buy” rating and issued a $11.00 target price on shares of Conatus Pharmaceuticals in a research report on Friday, May 5th. Zacks Investment Research lowered Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 21st. Stifel Nicolaus reissued a “buy” rating and set a $9.00 price target (up from $7.00) on shares of Conatus Pharmaceuticals in a report on Thursday, March 16th. FBR & Co reissued an “outperform” rating and set a $16.00 price target on shares of Conatus Pharmaceuticals in a report on Wednesday, March 15th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Conatus Pharmaceuticals in a report on Friday, March 17th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Conatus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $13.25.
Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 5.22 on Friday. The company has a 50 day moving average price of $6.83 and a 200-day moving average price of $4.60. Conatus Pharmaceuticals has a 52-week low of $1.45 and a 52-week high of $9.40. The firm’s market cap is $136.60 million.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.20. The firm had revenue of $7 million during the quarter, compared to analysts’ expectations of $5.88 million. During the same quarter in the previous year, the company posted ($0.35) EPS. Equities research analysts anticipate that Conatus Pharmaceuticals will post ($0.83) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Favorable Press Coverage Unlikely to Impact Conatus Pharmaceuticals (CNAT) Stock Price” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://transcriptdaily.com/2017/05/20/positive-press-coverage-unlikely-to-affect-conatus-pharmaceuticals-cnat-share-price-updated-updated-updated.html.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.